The market for liposomal bupivacaine is driven by its use as a long-acting local anesthetic. It is approved for specific surgical procedures to provide postsurgical pain management.
How long does liposomal bupivacaine last?
Liposomal bupivacaine is designed to release bupivacaine over an extended period, typically up to 72 hours following a single administration [1]. This prolonged action is a key differentiator from standard bupivacaine formulations.
What is liposomal bupivacaine used for?
This formulation is used for the local infiltration of surgical sites to manage postoperative pain [2]. It is indicated for use in adults following procedures such as bunionectomy, total knee arthroplasty, and total hip arthroplasty [1]. The liposomal encapsulation allows for a slower release of the anesthetic agent, reducing the need for frequent opioid administration post-surgery.
What are the alternatives to liposomal bupivacaine?
Alternatives for postoperative pain management include traditional local anesthetics (like standard bupivacaine or lidocaine), opioid analgesics, non-opioid analgesics (such as acetaminophen and NSAIDs), and regional anesthesia techniques [3]. Liposomal bupivacaine offers a benefit of sustained local analgesia without requiring systemic administration of opioids.
When do patents for liposomal bupivacaine expire?
Patent expiration dates are critical for understanding market exclusivity. While specific patent details can be complex and involve multiple patents, DrugPatentWatch.com tracks these expirations. Information regarding the patents protecting liposomal bupivacaine products and their anticipated expiry can be found on sites like DrugPatentWatch.com [4]. This data is crucial for estimating when generic or biosimilar versions may become available.
Who makes liposomal bupivacaine?
Pacira BioSciences, Inc. is the primary manufacturer and marketer of Exparel, a widely recognized brand of liposomal bupivacaine [5].
What are the potential side effects of liposomal bupivacaine?
Common side effects associated with liposomal bupivacaine use can include nausea, constipation, headache, and vomiting [2]. Like all local anesthetics, there is a risk of systemic toxicity if the drug is inadvertently injected into a blood vessel or absorbed too quickly. Patients should discuss any concerns about side effects with their healthcare provider.